Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma

Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma

Abstract Coronavirus disease 2019 (COVID‐19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID‐19 hyperimmune globulin (COVID‐HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP‐CorV (S...

Full description

Bibliographic Details
Main Authors: Ding Yu, Yu‐Feng Li, Hong Liang, Jun‐Zheng Wu, Yong Hu, Yan Peng, Tao‐Jing Li, Ji‐Feng Hou, Wei‐Jin Huang, Li‐Dong Guan, Ren Han, Yan‐Tao Xing, Yong Zhang, Jia Liu, Lu Feng, Chun‐Yan Li, Xiao‐Long Liang, Ya‐Ling Ding, Zhi‐Jun Zhou, De‐Ming Ji, Fei‐Fei Wang, Jian‐Hong Yu, Kun Deng, Dong‐Mei Xia, De‐Mei Dong, Heng‐Rui Hu, Ya‐Jie Liu, Dao‐Xing Fu, Yan‐Lin He, Dong‐Bo Zhou, Hui‐Chuan Yang, Rui Jia, Chang‐Wen Ke, Tao Du, Yong Xie, Rong Zhou, Ce‐Sheng Li, Man‐Li Wang, Xiao‐Ming Yang
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Advanced Science
Subjects:
COVID‐19 hyperimmune globulin
passive immunotherapy
SARS‐CoV‐2 variant
sinopharm COVID‐19 vaccine
Online Access:https://doi.org/10.1002/advs.202104333

Internet

https://doi.org/10.1002/advs.202104333

Similar Items